Candida krusei: biotechnological potentials and concerns about its safety

Area of Science:

• Biotechnology
• Mycology
• Medical Microbiology

Background:

• Yeasts, particularly Saccharomyces species, are widely used in biotechnology.
• Candida krusei is increasingly recognized for its biotechnological applications, including food fermentation and biochemical production.
• This yeast is also an opportunistic pathogen, posing risks to immunocompromised individuals.

Purpose of the Study:

• To explore the dual role of Candida krusei in biotechnology and clinical settings.
• To address the safety concerns associated with the industrial exploitation of Candida krusei.
• To highlight the challenges posed by Candida krusei's antifungal resistance.

Main Methods:

• Literature review on Candida krusei's isolation, applications, and pathogenicity.
• Analysis of Candida krusei's intrinsic resistance to antifungal agents, especially fluconazole.
• Assessment of the implications of increased immunosuppressive drug use on Candida krusei infections.

Main Results:

• Candida krusei is found in diverse environments, including fermented foods and dairy products.
• It serves as a source for producing biochemicals and enzymes.
• Candida krusei infections are prevalent in immunocompromised patients, including those with HIV/AIDS and cancer.

Conclusions:

• The opportunistic pathogenic nature of Candida krusei necessitates careful consideration for its safe industrial use.
• Intrinsic resistance to fluconazole, a primary antifungal drug, complicates treatment and safe application.
• Further research is needed to balance the biotechnological benefits with the clinical risks of Candida krusei.